Agilent acquires Biocare for $950M to boost pathology/cancer diagnostics and recurring revenue. Click here to read an analysis of A stock now.
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...
The table below is a review of notable updates that occurred in February 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results